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Abstract 
Objective To identify research priorities that have been answered, six years after being identified as 
important to people with epilepsy and epilepsy professionals.  
Background The DUETs database collates key unanswered questions identified by patients and 
professionals. In 2011, 398 questions were created using focus group methodologies. We wanted to 
know whether published research has since answered these important questions.  
Design The top 20 ranked questions for both patients and clinicians were studied. The PubMed and 
Cochrane databases were searched for published papers and NICE, SIGN and ILAE guidance for 
authoritative statements. The number of papers targeted at answering these research priorities was 
recorded.  
Results The questions from epilepsy professionals yielded 356 papers, 158 answering the topic. 
PatieŶts͛ ƋuestioŶs yielded 150 papers, of which 73 targeted the priorities. All pƌofessioŶals͛ 
questions were answered by a paper or guideline, as opposed to 75% of patieŶts͛ ƋuestioŶs.   
Conclusions Researchers are doing a fine job at answering research priorities that are of interest to 
them and their peers. Unanswered and important research priorities produced by patients and 
carers produce 46% as many papers, are addressed in 24% as many guidelines, or go unanswered 
entirely.  
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Introduction 
͞Nothing about them, without them͟ is the ĐlaƌioŶ Đall of those ǁho aƌe Đoŵŵitted to geŶuiŶe useƌ 
participation in research. The James Lind Alliance, brings patients, carers and clinicians together as 
priority sharing partnerships to ensure that research is targeted at questions that matter to these 
interested parties. In 2010 we contributed to the database of uncertainties of the effects of 
treatments (DUETS). 398 questions regarding treatments and their effects were produced from 
focus groups comprised of people with epilepsy, their carers and relatives – or epilepsy clinicians and 
researchers.[1] The questions were subsequently ranked by participants and thematically grouped to 
identify similarities and comparisons. The top ƌaŶked ƋuestioŶs ǁeƌe all deeŵed ͚uŶaŶsǁeƌed͛ at 
the time of publication following thorough scrutiny of online databases.[2] It was our hope by 
publishing the report and by uploading all questions to the NHS Evidence DUETs webpage [2] that 
we would encourage researchers to preferentially focus on these questions. Epilepsy was one of the 
first partnership exercises to be launched and we aim to assess the influence of the process since the 
priorities were published. We sought to identify if the top 20 ranked questions from professionals 
and patients had been answered over the last six years (supplementary data). 
 
Methods 
We searched the PubMed and Cochrane databases for published papers, and NICE, SIGN, ILAE, AES, 
NCS and EFNS guidance for authoritative statements (from January 1st 2010 to April 1st 2016). Papers 
ǁeƌe ƌated as ͚aŶsǁeƌiŶg͛ a ƋuestioŶ if they ĐoŶtaiŶed Ŷeǁ data that wholly or in part addressed the 
uncertainty. Review articles, most case reports and hypotheses without data were not included. We 
recorded the total number of papers yielded by the search strategy and the number that answered 
the question.  
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Results 
Clinicians and Researchers  Patients and Carers 
Question 
Rank 
Relevant 
papers 
identified 
Papers 
answering 
question 
Guidelines 
answering 
question 
Question 
Rank 
Relevant 
papers 
identified 
Papers 
answering 
question  
Guidelines 
answering 
question 
1 63 33 2 - NICE, 
SIGN 
1 27 24 0 
2 3 1 2 - NICE, 
SIGN 
2 2 2 1 – NICE 
3 36 20 
1 - SIGN 
3 50 11 1 – NICE 
4 1 1 
0 
4 Answered by question 1 
5 9 3 
0 
5 6 4 0 
6 10 0 
1 - SIGN 
6 2 1 0 
7 Answered by question 1 7 
12 
4 2 – NICE, 
SIGN 
8 21 12 
0 
8 2 2 1 – SIGN 
9 8 4 
1 - SIGN 
9 19 15 0 
10 Answered by question 8 10 
0 
0 0 
11 96 39 5 - NICE, 
SIGN, AESG, 
NCS, EFNS 
11 1 1 0 
12 Answered by question 11 12 
5 
2 0 
13 12 7 3 - SIGN, 
NCS, EFNS 
13 0 0 0 
14 0 0 
1 - NICE 
14 22 6 0 
15 9 3 
1 - SIGN 
15 Answered by question -3 
16 31 12 2 - NICE, 
SIGN 
16 2 1 0 
17 17 5 
1 - SIGN 
17 0 0 0 
18 9 5 2 - NICE, 
SIGN 
18 0 0 1 – SIGN 
19 22 11 
1 - SIGN 
19 0 0 0 
20 9 2 2 - NICE, 
SIGN 
20 0 0 0 
Table 1. The number of papers found relating to each question formulated by clinicians and 
researchers, and patients and carers, are listed. This number is split into the total number of papers 
identified by the search strategy, and the number of papers with new data relevant to the question 
that addresses each question. The guidelines relating to each question are also shown.  The clinician 
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questions clustered in several groups: prescribing in pregnancy (1, 7, 9, 20); prescribing choices and 
drug withdrawal (2, 4, 6, 14, 18); cognitive and psychiatric side effects (5, 15, 17, 19); non-epileptic 
attack disorder (8, 10); and status epilepticus (11, 12, 13). Patient questions clustered into themes 
about education (1, 4, 12); cognitive and psychiatric side effects (3, 5, 9, 15, 18); how to take 
medication and AED monitoring (2, 6, 7, 10, 17); and epilepsy service configuration (6, 20). 
 
 
Clinicians and researchers 
Three questions were adequately addressed by a similar question, leaving 17 unique questions 
(table 1). The status epilepticus questions had the most papers addressing them - 46 targeted papers 
from a total of 108 identified. ͚PƌesĐƌiďiŶg iŶ pƌegŶaŶĐy͛ aŶd ͚ĐogŶitiǀe aŶd psyĐhiatƌiĐ effeĐts͛ were 
next best answered, ǁith ϯϵ aŶd ϮϮ taƌgeted papeƌs ƌespeĐtiǀely. QuestioŶ ϵ, ͚Should the 
lamotrigine dose be pro-actively increased in pregnancy?͛, is the focus of an ongoing trial: EMPiRE 
Study – Anti-Epileptic drug Monitoring in PREgnancy: an evaluation of effectiveness, cost-
effectiveness and acceptability of monitoring strategies.[3] We identified no relevant papers for two 
questions (6 and 14).  
 
Patients and carers 
The top 20 questions from patients and carers produced 18 unique uncertainties (table 1). The top 
priority was addressed. The clusters that involved allied health professionals such as education (26 
targeted papers) and cognition and psychiatric effects (30 papers) were better answered than 
practical questions about how best to take the medication, and service configuration (7 and 1 papers 
respectively).  
 
Theƌe ǁeƌe ϭ5ϴ ƌeleǀaŶt papeƌs foƌ the ĐliŶiĐiaŶs͛ aŶd ƌeseaƌĐheƌs͛ ƋuestioŶs (ŵeaŶ ϵ.ϯ peƌ 
question, range 0-39) compared to 73 foƌ the patieŶt aŶd Đaƌeƌs͛ ƋuestioŶs (4.1 per question, range 
0-24). There was a trend for the questioŶs to get less ǁell aŶsǁeƌed as the ƋuestioŶ͛s ƌaŶkiŶg 
dropped. Fewer patient questions were addressed by national guidelines than the professioŶals͛ 
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questions (6 vs 25). All of the pƌofessioŶals͛ ƋuestioŶs ǁeƌe answered by research or guidelines, 
compared to 15 of the patieŶts͛ ƋuestioŶs.  
 
Discussion 
We recognise that our research strategies were not exhaustive and were unblinded. We 
demonstrate that researchers could be doing more to answer the questions that matter to patients 
with epilepsy. In contrast researchers are doing a fine job at answering research priorities that are of 
interest to them and their peers. Research priorities produced by patients and carers produce only 
46% as many papers, are addressed in only 24% as many guidelines, and often go unanswered 
entirely. This is despite patient questions often being more tangible and practical. Many of these 
practical questions remain entirely unanswered. Interestingly, with question 18 (over diagnosis of 
depression in epilepsy), there was much new research about the link between epilepsy and 
depƌessioŶ, ďut Ŷo ƌesults speĐifiĐally aŶsǁeƌiŶg the patieŶts͛ ƋuestioŶ. This iŶdiĐates that ƌeseaƌĐh 
in this area is happening, but not being focussed to areas with keen patient interest.  
We suspect that ŵaŶy of the pƌofessioŶals͛ ƋuestioŶs ǁeƌe Đƌeated aŶd ƌated highly ďeĐause they 
were aware of the literature, ongoing research, and because they keep up-to-date with 
controversies. In contrast, ŵaŶy of the patieŶts͛ ƋuestioŶs do Ŷot haǀe the ƌeseaƌĐh ŵoŵentum and 
appear de novo. Many of these questions could be considered partially answered, and now it would 
be useful to create a more specific list of questions relating to each of the broadly 'answered' topics. 
Examples of true evidence gaps are management when initial epilepsy treatment fails, and how 
effective second line treatment is, following initial treatment failure. 
Other priority setting partnerships using the DUETs model have looked at the dissemination and 
impact of their priorities. The childhood disability group asked the Health Technology Assessment 
(HTA) and Health Services and Delivery Research (HS&DR) programmes to identify which of their top 
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questions were the focus of successful funding awards.[4] A year after publication, two were being 
answered: the top priority regarding therapeutic regimens, the tenth focussing on sleep disturbance; 
and a third was the subject of NICE guidance in preparation. The Palliative Care group͛s pƌioƌities 
gained immediate traction within their community.[5] The All Ireland Institute of Hospice and 
Palliative Care arranged a local prioritisation workshop, to reprioritise the longlist to their local 
circumstances. Using the UK Clinical Research Collaboration (UKCRC) database they undertook a 
research mapping exercise to identify the grants that may answer their top questions. They have 
taken the process further by both reviewing the out of scope questions and, with the Motor 
Neurone Disease Association, directly commissioning research that answers their longlist of 
priorities.  We suggest that it is time for a new epilepsy priority sharing partnership to be convened 
using the James Lind Alliance model and we hope that the priorities that they produce can capture 
the imaginations of charities, grant administering bodies and researchers.  
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